GPI to present research at ISPOR

GPI will be presenting research posters at ISPOR US, held at the Gaylord Convention Centre, Maryland on 15-18 May.

15-18 May 2022, In-Person & Virtual Conference

GPI will be attending and presenting our research at ISPOR, held at the Gaylord Resort & Convention Center, Washington D.C, United States on 15-18 May 2022. Our representatives will be onsite and on hand to discuss how GPI can optimise your pricing and market access decision-making in 2022 and beyond. In addition, GPI will be presenting three research posters, and will taking part in a live panel discussion ‘What Is the Preferred Approach to US Drug Pricing Reforms: International Reference Pricing or Value Based Pricing?‘. The posters will be available throughout the conference, and the panel discussion will be taking place on Monday 16 May, 10:15am-11:15am, Concurrent Breakout Session one.

ISPOR Research Posters

Forecasting Drug Price for Reimbursement By Utilizing a Value-Price Relationship, a Case Study in Hormone-Relapsed Prostate Cancer

Due to the different evidence requirements and archetypes of HTA bodies, forecasting the value of a new product is a challenge. Value and price are correlated and can be applied to determine the price of new products. The aim of this study was to forecast and validate the price of darolutamide in England, France and Germany using a value framework approach.

The impact of value-based pricing (VBP) vs. international reference pricing (IRP) on innovative drugs in the US

Objective: To compare IRP to VBP, for a list of innovative drugs to understand how commonly-utilised pricing policies in regulated markets may impact drug prices in the US.

List prices for Medicare negotiation-eligible medicines targeted by Build Back Better drug pricing provisions estimated to be reduced by over 40% on average

The Build Back Better social spending bill recently passed in the House of Representatives on 19 November includes unprecedented drug pricing controls for drugs covered under Medicare, including empowering the program to negotiate prices for up to 10 highest-cost Medicare drugs annually, starting from 2025 for Part D and 2027 for Part B, and establishing inflation rebates that could notably temper the rate of drug price increases over time. This research analysis aims to identify the drugs likely to be targeted by the Medicare negotiation provision of the proposed legislation.

ISPOR Panel Discussion: IP1: What Is the Preferred Approach to US Drug Pricing Reforms: International Reference Pricing or Value Based Pricing?

Monday May 16, 10:15am – 11:15am, Concurrent Breakout Session 1

Voted top 10 HEOR trends of 2022

We’re pleased to announce that we will also be taking part in a panel discussion, alongside colleagues from Aetion, Duke-Margolis Center for Health Policy and PhRMA. The panel discussion will focus on ‘What Is the Preferred Approach to US Drug Pricing Reforms: International Reference Pricing or Value Based Pricing?’.

The call for drug pricing reform in the United States has amplified over the past two administrations and legislation has been drafted, though not passed. IRP and VBP based on cost-effectiveness are leading the proposed reform conversations, however, it is unclear how much impact these reforms would have on actual drug pricing, patient access and affordability, value and innovation. Using an analysis comparing IRP and VBP for 23 drugs across 28 indications as a baseline understanding of the approaches, the panel will debate the results and their preferred approaches to reforms in the US.

web page image

Share the Article: